Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia | Zendy

Hagop M. Kantarjian | Zendy; Daniel J. DeAngelo | Zendy; Matthias Stelljes | Zendy; Giovanni Martinelli | Zendy; Michaela Liedtke | Zendy; Wendy Stock | Zendy; Nicola Gökbuget | Zendy; Susan O’Brien | Zendy; Kongming Wang | Zendy; Tao Wang | Zendy; M. Luisa Paccagnella | Zendy; Barbara Sleight | Zendy; Erik Vandendries | Zendy; Anjali S. Advani | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

Author(s) -

Hagop M. Kantarjian,

Daniel J. DeAngelo,

Matthias Stelljes,

Giovanni Martinelli,

Michaela Liedtke,

Wendy Stock,

Nicola Gökbuget,

Susan O’Brien,

Kongming Wang,

Tao Wang,

M. Luisa Paccagnella,

Barbara Sleight,

Erik Vandendries,

Anjali S. Advani

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1509277

Subject(s) - calicheamicin , medicine , lymphoblastic leukemia , refractory (planetary science) , cd22 , gemtuzumab ozogamicin , oncology , acute lymphocytic leukemia , leukemia , antibody , immunology , monoclonal antibody , cd33 , stem cell , physics , astrobiology , cd34 , biology , genetics

The prognosis for adults with relapsed acute lymphoblastic leukemia is poor. We sought to determine whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, results in better outcomes in patients with relapsed or refractory acute lymphoblastic leukemia than does standard therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research